FDA Poised to Approve New Alzheimer's Drug
We talk about the latest advances in Alzheimer's research.
January 4, 2023
55 min
Full
1,615 of 3,393
January 4, 2023
FDA Poised to Approve New Alzheimer's Drug
0:00 / 55:48
Excerpt playback isn’t available for this episode — use the full-episode link.
Search the Record
Moment search isn’t open for this episode yet
When it opens, you’ll be able to type any phrase and jump straight to the second it was said.
America the Jesuit Review Episodes Around January 4, 2023
Episode 1,615 of 3,393 — walk the feed in the order it was published.
55:48This episodeFDA Poised to Approve New Alzheimer's Drug
Summary
The U.S. Food and Drug Administration is expected to approve the experimental dementia drug Lecanemab as soon as this week, a move embraced by Alzheimer's disease researchers after trials showed it slowed the progression of the disease in some patients with mild cognitive impairment. The new potential therapy is also raising hopes that it could help those who are symptom-free but have brain changes -- detected by new blood tests -- that signal Alzheimer's. We'll talk about the latest advances in Alzheimer's research.
Guests:
Dr. Adam Boxer, endowed professor in memory and aging and professor of neurology, UCSF - He directs UCSF’s Neurosciences Clinical Research Unit and the Alzheimer’s Disease and Frontotemporal Degeneration Clinical Trials Program at the UCSF Memory and Aging Center.
Dr. Kristine Yaffe, professor of psychiatry, neurology and epidemiology, UCSF - She also directs UCSF's Center for Population Brain Health.
Dr. Michael Weiner, professor of radiology, UCSF - principal investigator of the Alzheimer's Disease Neuroimaging Initiative
Learn more about your ad choices. Visit megaphone.fm/adchoices
Episode details and artwork are published by the show’s own feed. Sentinel plays short cited excerpts and links every episode back to its publisher.